Riskpilot← Back to searchSign inGet full accessDextech Medical AB
ABActiveOrg 5566646203UppsalaResearch and experimental development on natural sciences and engineering · NACE 7210Est. 20041 employees
Revenue 2025
SEK 0
EBITDA margin
—
+41% vs 2024
Equity ratio
98.7%
Financial strength
Net profit 2025
SEK -4,8M
-3% vs 2024
| Revenue | SEK 0 | — |
| EBITDA | SEK -1,1M | +41% |
| Net profit | SEK -4,8M | -3% |
| Total assets | SEK 25,1M | -18% |
| Equity | SEK 24,8M | -16% |
| Employees | 1 | — |
Legal name
Dextech Medical AB
Org number
5566646203
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
9 augusti 2004
Share capital
SEK 832 000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-06-30
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna Dessutom har verkställande direktören rätt att teckna firmanbeträffande löpande förvaltningsåtgärder
Company purpose
Bolaget skall bedriva verksamhet med bioteknologisk/biomedicinsk forskning, utveckling av nya läkemedelsprototyper inom onkologi och icke maligna sjukdomar, utlicensiering av mogna projekt till läkemedels/bioteknikindustri samt därmed förenlig verksamhet.
Address
Uppsala
Email
arh@telia.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | 0 | 0 | 0 | 635 | 3 116 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — | — | — | — | — | — | — |
| EBITDA | −458 | −1 116 | −1 083 | −1 337 | −2 098 | −1 949 | −2 241 | −1 875 | −1 860 | −1 104 |
| Depreciation & amort. | −5 620 | −6 760 | −7 730 | −7 019 | −5 616 | −4 126 | −3 029 | −3 064 | −3 689 | −4 214 |
| EBIT | −6 078 | −7 876 | −8 813 | −8 356 | −7 714 | −6 075 | −5 270 | −4 939 | −5 549 | −5 318 |
| Net financials | 19 | — | — | — | — | — | — | 349 | 843 | 474 |
| Profit before tax | −6 059 | −7 876 | −8 813 | −8 356 | −7 714 | −6 075 | −5 270 | −4 590 | −4 706 | −4 845 |
| Tax | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| Net profit | −6 059 | −7 876 | −8 813 | −8 356 | −7 714 | −6 075 | −5 270 | −4 590 | −4 706 | −4 845 |
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 22 847 | 29 738 | 20 763 | 22 431 | 13 344 | 7 234 | 39 589 | 35 031 | 30 588 | 25 100 |
| Equity | 22 084 | 28 735 | 19 923 | 20 805 | 13 091 | 7 016 | 38 878 | 34 313 | 29 608 | 24 763 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 763 | 1 003 | 840 | 1 626 | 253 | 218 | 712 | 718 | 980 | 337 |
| Total debt | 763 | 1 003 | 840 | 1 626 | 253 | 218 | 712 | 718 | 980 | 337 |
EBITDA margin
-110400000.0%
This company
15.8%
Market median
-698734277% vs market
20162025
Equity ratio
98.7%
This company
38.2%
Market median
+158% vs market
20162025
Return on equity
-19.6%
This company
18.4%
Market median
-207% vs market
20162025
Net profit margin
-484500000.0%
This company
8.1%
Market median
-5981481581% vs market
20162025
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20162025
Debt / equity
0.01×
This company
0.62×
Market median
+98% vs market
20162025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-07-01 – 2025-06-30
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-07-01 – 2024-06-30
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-07-01 – 2023-06-30
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-07-01 – 2022-06-30
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-07-01 – 2021-06-30
- Annual report 2020Filed via Bolagsverket / SCB · Period 2019-07-01 – 2020-06-30
- Annual report 2019Filed via Bolagsverket / SCB · Period 2018-07-01 – 2019-06-30
- Annual report 2018Filed via Bolagsverket / SCB · Period 2017-07-01 – 2018-06-30
- Annual report 2017Filed via Bolagsverket / SCB · Period 2016-07-01 – 2017-06-30
- Annual report 2016Filed via Bolagsverket / SCB · Period 2015-07-01 – 2016-06-30
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
PG Chief Auditor | Chief Auditor | 2025 | — | — |
TS Chief Auditor | Chief Auditor | 2022 | — | — |
TS Chief Auditor | Chief Auditor | 2022 | — | — |
HF Chief Auditor | Chief Auditor | 2025 | — | — |
AR Chief Executive Officer | Chief Executive Officer | 2022 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2022 | — | — | |
| Chairman | 2022 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Dextech Medical AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Per Gustaf Hammar | Chief Auditor | 0 companies |
| Thomas Stig Patrik Sandberg | Chief Auditor | 0 companies |
| Thomas Stig Patrik Sandberg | Chief Auditor | 0 companies |
| Halvar Folke Mattias Lötborn | Chief Auditor | 0 companies |
| Anders Ragnarson Holmberg | Chief Executive Officer | 0 companies |
| Per-Olov Asplund | Board of Directors | 0 companies |
| Svante Karl-Johan Wadman | Board of Directors | 0 companies |
| Rolf Weste Eriksson | Board of Directors | 0 companies |
| Sten Folke Nilsson | Board of Directors | 0 companies |
| Peter James Arthur Benson | Board of Directors | 0 companies |
| Rutger Andreas Segerros | Chairman | 0 companies |